Ignite Creation Date:
2025-12-24 @ 9:07 PM
Ignite Modification Date:
2026-01-04 @ 5:36 PM
Study NCT ID:
NCT04600804
Status:
COMPLETED
Last Update Posted:
2025-12-24
First Post:
2020-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Role of 18F-FDG-PET for Staging and Prognostication
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020522', 'term': 'Lymphoma, Mantle-Cell'}], 'ancestors': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'RETROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 200}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-10-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2025-07-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-18', 'studyFirstSubmitDate': '2020-10-19', 'studyFirstSubmitQcDate': '2020-10-19', 'lastUpdatePostDateStruct': {'date': '2025-12-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-10-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-10-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Sensitivity (proportion) and agreement (Cohen K) of PET results (performed in different time points) compared to the current standard (TC plus bone marrow biopsy).', 'timeFrame': '24 months', 'description': 'To better define the role of PET for the staging of MCL patients at the time of diagnosis, for evaluation of response after induction treatment (pre-ASCT; i-PET) and post ASCT (eot-PET) in comparison to the current standards, namely computed axial tomography (CT) and bone marrow biopsy.'}, {'measure': 'C-index, estimated comparing models adding or not PET parameters to standard prognostic factors in predicting PFS.', 'timeFrame': '24months', 'description': 'To build a new prognostic model for PFS, including PET parameters, MIPI-b and biological data (e.g. MRD, GEP and mutational parameters).The achievement of these objectives could help to plan futures studies in order to improve the outcome of MCL patients.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['prognostic issues', 'PET review', 'MCL'], 'conditions': ['Mantle Cell Lymphoma']}, 'descriptionModule': {'briefSummary': 'A retrospective, multicenter, non-interventional, imaging study ancillary to FIL\\_MCL0208 clinical trial (NCT02354313) in untreated adult patients with mantle cell lymphoma.', 'detailedDescription': 'This is a retrospective, multicenter, non-interventional, imaging study devoted to patients diagnosed with MCL and enrolled in the MCL0208 international randomized, phase III clinical trial (NCT02354313).\n\nThe study is aimed at addressing a number of prognostic issues that still need to be clarified in MCL patients, by taking advantage of the PET performed within the MCL0208 trial and available for the analysis, and the clinical records and molecular data generated in the context of the trial.\n\nIn the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after-ASCT (eot-PET), and none of the exams was used in the decisionmaking strategy. All the PETs available will be collected and considered for analysis. The study will not require additional treatment or procedures except those required for the MCL0208 trial. The participation of the patient to the MCL0208 trial is a pre-requisite to be involved in this study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'A total of 300 patients have been enrolled in the MCL0208 trial. We expect to analyze the PETs, clinical and biological data of about 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Enrollment of the patient in the MCL0208 clinical trial documented by the signature of the study informed consent;\n* Patient's treatment in one of the centers that participated in the MCL0208 trial and that has joined the MCL0208-PET study as well;\n* Evidence of signed informed consent for the MCL0208-PET study."}, 'identificationModule': {'nctId': 'NCT04600804', 'briefTitle': 'The Role of 18F-FDG-PET for Staging and Prognostication', 'organization': {'class': 'OTHER', 'fullName': 'Fondazione Italiana Linfomi - ETS'}, 'officialTitle': 'The Role of 18F-FDG-PET for Staging and Prognostication in Patients Enrolled in the Fondazione Italiana Linfomi (FIL) MCL0208 Trial', 'orgStudyIdInfo': {'id': 'FIL_MCL0208-PET'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'All patients registered in the MCL0208 trial', 'description': 'About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.\n\nIn the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '73100', 'city': 'Lecce', 'state': 'Apulia', 'country': 'Italy', 'facility': 'Ematologia Ospedale Vito Fazzi', 'geoPoint': {'lat': 40.35481, 'lon': 18.17244}}, {'zip': '73039', 'city': 'Tricase', 'state': 'Apulia', 'country': 'Italy', 'facility': 'U.O.C Ematologia e Trapianto A.O. C. Panico', 'geoPoint': {'lat': 39.93018, 'lon': 18.35421}}, {'zip': '29121', 'city': 'Piacenza', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'U.O.Ematologia Ospedale Guglielmo da Saliceto', 'geoPoint': {'lat': 45.05242, 'lon': 9.69342}}, {'zip': '42123', 'city': 'Reggio Emilia', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'Ematologia Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'zip': '47923', 'city': 'Rimini', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'U.O. di Ematologia Ospedale degli Infermi di Rimini', 'geoPoint': {'lat': 44.05755, 'lon': 12.56528}}, {'zip': '33081', 'city': 'Aviano', 'state': 'Friuli Venezia Giulia', 'country': 'Italy', 'facility': 'S.O.C. Oncologia Medica A Centro Riferimento Oncologico', 'geoPoint': {'lat': 46.07056, 'lon': 12.59472}}, {'zip': '33100', 'city': 'Udine', 'state': 'Friuli Venezia Giulia', 'country': 'Italy', 'facility': 'SOC Clinica Ematologica Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'zip': '00168', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'Ematologia Universitа Cattolica S. Cuore', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '16132', 'city': 'Genoa', 'state': 'Liguria', 'country': 'Italy', 'facility': 'Ematologia Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia', 'geoPoint': {'lat': 44.40478, 'lon': 8.94439}}, {'zip': '16132', 'city': 'Genoa', 'state': 'Liguria', 'country': 'Italy', 'facility': 'U.O. Clinica Ematologica Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l Oncologia', 'geoPoint': {'lat': 44.40478, 'lon': 8.94439}}, {'zip': '25123', 'city': 'Brescia', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Ematologia ASST Spedali Civili di Brescia', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'zip': '20122', 'city': 'Milan', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Ematologia Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '20162', 'city': 'Milan', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'SC Ematologia ASST Grande Ospedale Metropolitano Niguarda', 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '20900', 'city': 'Monza', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Ematologia ASST MONZA Ospedale S. Gerardo', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'zip': '27100', 'city': 'Pavia', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Div. di Ematologia IRCCS Policlinico S. Matteo di Pavia', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'U.O. Ematologia Istituto Clinico Humanitas', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'city': 'Milan', 'state': 'Milan', 'country': 'Italy', 'facility': 'Unità Linfomi - Dipartimento Oncoematologia - Istituto Scientifico San Raffaele', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '15121', 'city': 'Alessandria', 'state': 'Piedmont', 'country': 'Italy', 'facility': 'S.C. Ematologia A.O. SS. Antonio e Biagio e Cesare Arrigo', 'geoPoint': {'lat': 44.90924, 'lon': 8.61007}}, {'zip': '12100', 'city': 'Cuneo', 'state': 'Piedmont', 'country': 'Italy', 'facility': 'S.C. di Ematologia e Trapianto di Midollo Osseo A.O. S. Croce e Carle', 'geoPoint': {'lat': 44.39071, 'lon': 7.54828}}, {'zip': '28100', 'city': 'Novara', 'state': 'Piedmont', 'country': 'Italy', 'facility': 'SCDU Ematologia AOU Maggiore della Caritа di Novara', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'zip': '10126', 'city': 'Turin', 'state': 'Piedmont', 'country': 'Italy', 'facility': 'Ematologia Universitaria A.O.U. Citta della Salute e della Scienza di Torino', 'geoPoint': {'lat': 45.07049, 'lon': 7.68682}}, {'zip': '10126', 'city': 'Turin', 'state': 'Piedmont', 'country': 'Italy', 'facility': 'S.C.Ematologia A.O.U. Citta della Salute e della Scienza di Torino', 'geoPoint': {'lat': 45.07049, 'lon': 7.68682}}, {'zip': '09121', 'city': 'Cagliari', 'state': 'Sardinia', 'country': 'Italy', 'facility': 'SC Ematologia e CTMO Ospedale Businco', 'geoPoint': {'lat': 39.23054, 'lon': 9.11917}}, {'zip': '98158', 'city': 'Messina', 'state': 'Sicily', 'country': 'Italy', 'facility': 'S.C. Ematologia Azienda Ospedali Riuniti Papardo-Piemonte', 'geoPoint': {'lat': 38.19394, 'lon': 15.55256}}, {'zip': '90146', 'city': 'Palermo', 'state': 'Sicily', 'country': 'Italy', 'facility': 'Divisione di Ematologia A.O. Ospedali Riuniti Villa Sofia-Cervello', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'zip': '39100', 'city': 'Bolzano', 'state': 'Trentino-Alto Adige', 'country': 'Italy', 'facility': 'Divisione di Ematologia e T.M.O. - Ospedale Centrale di Bolzano', 'geoPoint': {'lat': 46.49067, 'lon': 11.33982}}, {'zip': '50141', 'city': 'Florence', 'state': 'Tuscany', 'country': 'Italy', 'facility': 'Unitа funzionale di Ematologia Azienda Ospedaliera Universitaria Careggi', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'zip': '05100', 'city': 'Terni', 'state': 'Umbria', 'country': 'Italy', 'facility': 'S.C. Oncoematologia A.O. S. Maria di Terni', 'geoPoint': {'lat': 42.56335, 'lon': 12.64329}}, {'zip': '31100', 'city': 'Treviso', 'state': 'Veneto', 'country': 'Italy', 'facility': 'S.C di Ematologia Ospedale Ca Foncello', 'geoPoint': {'lat': 45.66673, 'lon': 12.2416}}, {'zip': '37134', 'city': 'Verona', 'state': 'Veneto', 'country': 'Italy', 'facility': 'U.O. Ematologia AOU Integrata di Verona', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'zip': '47014', 'city': 'Meldola', 'country': 'Italy', 'facility': 'Ematologia - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'city': 'Pisa', 'country': 'Italy', 'facility': 'U.O. Ematologia - AOU Pisana', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'city': 'Trieste', 'country': 'Italy', 'facility': 'Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Instituto Português de Oncologia de Lisboa', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}], 'overallOfficials': [{'name': 'Michael Mian, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Italy'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fondazione Italiana Linfomi - ETS', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}